UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
Treatment-resistant Depression Recent News
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Magic Mushrooms to Treat Anorexia? All About Compass' Novel Phase 2 Trial Of Psychedelic's Main Compound
Magic Mushrooms Are More Effective Than Antidepressants In Treating Depression, New Study Shows
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying